Sarepta Therapeutics, Inc.SRPTEarnings & Financial Report
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.
SRPT Q4 FY2025 Key Financial Metrics
Revenue
$369.6M
Gross Profit
N/A
Operating Profit
$-411.6M
Net Profit
$-412.2M
Gross Margin
N/A
Operating Margin
-111.4%
Net Margin
-111.5%
YoY Growth
-42.1%
EPS
$-3.92
Sarepta Therapeutics, Inc. Q4 FY2025 Financial Summary
Sarepta Therapeutics, Inc. reported revenue of $369.6M (down 42.1% YoY) for Q4 FY2025, with a net profit of $-412.2M (down 359.2% YoY) (-111.5% margin).
Key Financial Metrics
| Total Revenue | $369.6M |
|---|---|
| Net Profit | $-412.2M |
| Gross Margin | N/A |
| Operating Margin | -111.4% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Sarepta Therapeutics, Inc. Q4 FY2025 revenue of $369.6M breaks down across 3 segments, led by Pmo Products at $202.5M (54.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Pmo Products | $202.5M | 54.8% |
| Elevidys | $110.4M | 29.9% |
| Other | $56.7M | 15.3% |
Sarepta Therapeutics, Inc. Revenue by Segment — Quarterly Trend
Sarepta Therapeutics, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Pmo Products and Elevidys) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Pmo Products | $202.5M | $209.1M | $202.9M | $185.8M |
| Elevidys | $110.4M | $131.5M | $281.9M | $375.0M |
| Other | $56.7M | $29.4M | $28.4M | $50.7M |
Sarepta Therapeutics, Inc. Annual Revenue by Year
Sarepta Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.9B).
Sarepta Therapeutics, Inc. Quarterly Revenue & Net Profit History
Sarepta Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $369.6M | -42.1% | $-412.2M | -111.5% |
| Q3 FY2025 | $370.0M | -13.9% | $-50.6M | -13.7% |
| Q2 FY2025 | $513.1M | +42.3% | $196.9M | 38.4% |
| Q1 FY2025 | $611.5M | +70.1% | $-447.5M | -73.2% |
| Q4 FY2024 | $638.2M | +74.8% | $159.0M | 24.9% |
| Q3 FY2024 | $429.8M | +38.9% | $33.6M | 7.8% |
| Q2 FY2024 | $360.5M | +50.9% | $6.5M | 1.8% |
| Q1 FY2024 | $359.5M | +55.3% | $36.1M | 10.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $359.5M | $360.5M | $429.8M | $638.2M | $611.5M | $513.1M | $370.0M | $369.6M |
| YoY Growth | 55.3% | 50.9% | 38.9% | 74.8% | 70.1% | 42.3% | -13.9% | -42.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $3.22B | $3.42B | $3.60B | $3.96B | $3.47B | $3.68B | $3.49B | $3.35B |
| Liabilities | $2.26B | $2.35B | $2.38B | $2.44B | $2.32B | $2.32B | $2.17B | $2.21B |
| Equity | $961.2M | $1.08B | $1.22B | $1.53B | $1.14B | $1.36B | $1.32B | $1.14B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-242.1M | $14.9M | $-70.7M | $92.0M | $-583.4M | $261.3M | $-14.6M | $131.2M |